King Luther Capital Management Corp Raises Holdings in DexCom, Inc. (NASDAQ:DXCM)

King Luther Capital Management Corp increased its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 35.9% in the 3rd quarter, HoldingsChannel reports. The firm owned 213,245 shares of the medical device company’s stock after buying an additional 56,365 shares during the quarter. King Luther Capital Management Corp’s holdings in DexCom were worth $14,296,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of DXCM. Capital Insight Partners LLC lifted its position in shares of DexCom by 2.5% in the second quarter. Capital Insight Partners LLC now owns 3,690 shares of the medical device company’s stock valued at $418,000 after acquiring an additional 90 shares in the last quarter. HM Payson & Co. boosted its stake in shares of DexCom by 6.0% during the 1st quarter. HM Payson & Co. now owns 1,780 shares of the medical device company’s stock worth $247,000 after purchasing an additional 100 shares during the last quarter. Clear Creek Financial Management LLC grew its holdings in shares of DexCom by 4.2% during the second quarter. Clear Creek Financial Management LLC now owns 2,961 shares of the medical device company’s stock worth $336,000 after buying an additional 120 shares in the last quarter. SeaCrest Wealth Management LLC raised its position in shares of DexCom by 3.6% in the second quarter. SeaCrest Wealth Management LLC now owns 4,421 shares of the medical device company’s stock valued at $501,000 after buying an additional 152 shares during the last quarter. Finally, Securian Asset Management Inc. lifted its stake in shares of DexCom by 0.7% during the second quarter. Securian Asset Management Inc. now owns 22,866 shares of the medical device company’s stock valued at $2,593,000 after buying an additional 161 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Trading Down 1.0 %

Shares of DXCM opened at $74.48 on Friday. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The stock’s 50-day moving average is $70.43 and its two-hundred day moving average is $90.34. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The stock has a market cap of $29.09 billion, a PE ratio of 44.60, a P/E/G ratio of 2.30 and a beta of 1.17.

Insider Buying and Selling

In other news, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now directly owns 264,915 shares in the company, valued at approximately $18,318,872.25. This represents a 0.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the sale, the executive vice president now directly owns 75,451 shares in the company, valued at $5,217,436.65. This trade represents a 0.56 % decrease in their position. The disclosure for this sale can be found here. 0.30% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several analysts have commented on DXCM shares. BTIG Research lowered their target price on shares of DexCom from $156.00 to $120.00 and set a “buy” rating for the company in a research note on Friday, July 26th. Oppenheimer reduced their target price on DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Barclays lowered their price target on DexCom from $138.00 to $113.00 and set an “equal weight” rating for the company in a report on Monday, July 29th. Sanford C. Bernstein increased their price objective on shares of DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a report on Friday, October 25th. Finally, UBS Group lowered their target price on shares of DexCom from $163.00 to $95.00 and set a “buy” rating for the company in a report on Friday, July 26th. Seven research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, DexCom presently has an average rating of “Moderate Buy” and an average target price of $104.59.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.